IRF3 and endometrial cancer: Western blotting assay found that in five endometrial cancer cell lines, compared to the control group, AZD1775 treatment did not significantly alter the expression of total TBK1 and IRF3, but notably upregulated the expression of pTBK1 and pIRF3 (Figure 6A).